This website uses cookies to enhance the user experience.
||
A

ANINOVA AS916 135 513

Research
Limited company
Storhamargata 44 2317 HAMAR, Norge
Services
/ Research
/ 72.110 Research and experimental development on biotechnology

ANINOVA AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO
MH

Marte Holt Wetten1976

Chairman of the board
OE

Olav Eik-Nes1957

Years since formation
10 years
since Oct 27, 2015
Type
Limited company
VAT registered
Yes
Number of employees
0

Ownership

Number of shares and share classes
101
1 share class
Total number of shareholders
1
company
Belongs to group of

Financials

Total operating income 2024
2,607,378
NOK
Annual total result 2024
-158,490
NOK
Total equity 2024
485,992
NOK
Last update: Jul 9, 2025

Management

Management / administration

NameRoleShares
MH

Marte Holt Wetten

1976

Managing Director/CEO-

Board

NameRoleShares
OE

Olav Eik-Nes

1957

Chairman-
TA

Torunn Aasmundstad

1974

Board Member-
JU

Jørn Ulheim

1969

Board Member-

Others

NameRoleShares
P
PRICEWATERHOUSECOOPERS AS
Accountant-
Last update: Jun 16, 2023

Ownership

Company shareholders

NameShare classTotal number of sharesShare
N
NORSVIN SA
Ordinary shares
101
100 %
Last update: Jun 2, 2025

Group structure

  • NORSVIN SA
    Total operating income 2024: NOK 291,972,772
    Operating profit 2024: NOK 21,643,453
    Employees: 117

Financials

in NOK

Summary

Year2024202320222021
Total operating income
2,607,378
2,313,395
1,170,634
1,396,160
Annual Total Result
-158,490
389,809
-205,688
142,924
Total assets
2,003,454
3,116,664
1,271,601
1,365,019
Total liabilities
1,517,462
2,472,183
1,016,928
904,658
Total equity
485,992
644,481
254,672
460,361

P&L

Year2024202320222021
Total operating income
2,607,378
2,313,395
1,170,634
1,396,160
Total operating costs
2,703,249
1,955,187
1,385,603
1,255,115
Operating result
-95,871
358,208
-214,969
141,045
Financial income/costs
-62,619
31,601
9,281
1,879
Profit before tax
-158,490
389,809
-205,688
142,924
Total tax & extraordinary income/cost
0
0
0
0
Annual Total Result
-158,490
389,809
-205,688
142,924

Balance overview

Year2024202320222021
Total fixed assets
962,705
1,356,500
0
0
Total current assets
1,040,749
1,760,164
1,271,601
1,365,019
Total assets
2,003,454
3,116,664
1,271,601
1,365,019
Short term debt
672,262
1,415,683
1,016,928
904,658
Long term debt
845,200
1,056,500
0
0
Total liabilities
1,517,462
2,472,183
1,016,928
904,658
Contributed capital
254,672
254,672
254,672
317,437
Retained earnings
231,319
389,809
0
142,924
Total equity
485,992
644,481
254,672
460,361
Total equity and liabilities
2,003,454
3,116,664
1,271,601
1,365,019

Classification

Category
Type of organization
Limited company
Classification of institutional sector
INNL
Domestic sectors
A_IKKE-FIN
Non-financial corporations
2100
Private non-financial incorporated enterprises
Standard industrial classification
M
Main industrial area
Professional, scientific and technical activities
72
Activity
Scientific research and development
72.1
Main industrial group
Research and experimental development on natural sciences and engineering
72.11
Industrial group
Research and experimental development on biotechnology
72.110
Industrial group
Research and experimental development on biotechnology